Reference number : GC-2017-Q1-00385, amendment number : , agreement type : G, recipient legal name : Allen, Christine (University of Toronto), recipient country : CA, recipient province : nan, recipient city : Ontario, recipient postal code : nan, program name english : Engage Grants for Universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : Domtar is the largest integrated producer of uncoated free sheet paper in North America. As a result they are a_x000D_
major producer of lignin, a relatively low value by-product that is used as a solid fuel to generate process steam_x000D_
and power. Lignin, a substance in the cellular walls of plants, is the second most abundant renewable carbon_x000D_
source on our planet. Domtar has recently produced high-grade USDA Certified bio-based lignin, referred to as_x000D_
BioChoice lignin for potential applications in the energy and chemical industries. For the first time, the_x000D_
proposed research intends to explore Domtar's proprietary BioChoice lignin and derivatives, to be synthesized_x000D_
through this research, for applications in drug delivery. It is expected that this research will result in new_x000D_
intellectual property for Domtar and bring its proprietary material BioChoice into the pharmaceutical realm._x000D_
Domtar's proprietary BioChoice Kraft lignin is produced from the black liquor of the Plymouth mill at a rate of_x000D_
about 50-100 tons per day. While the Plymouth mill was the first commercial demonstration plant, Domtar also_x000D_
has 11 other pulp mills, four of which are in Canada. It is Domtar's intention to build out their lignin capacity in_x000D_
many or all of these facilities as demands and markets grow. Given lignin's low cost, sustainability, resistance_x000D_
to oxidation, biocompatibility and biodegradability it is of interest for use in biomedical applications. Yet to_x000D_
date, very few studies have explored lignin and its derivatives for applications in drug delivery. The goal of the_x000D_
current research is to synthesize and fully characterize BioChoice lignin-based microparticles that provide_x000D_
sustained release of drugs for veterinary applications. The global animal healthcare market, was valued at_x000D_
US$27.8 billion in 2013 and is expected to reach US$41.9 billion in 2019. New technologies that provide_x000D_
controlled delivery of drugs for maintenance of good health and treatment of diseases in companion and_x000D_
commercial animals will further advance this fast growing industry. Growth in this industry in Canada will_x000D_
result in new opportunities for scientists trained in chemistry as well as pharmaceutical and veterinary sciences., program purpose french : Domtar is the largest integrated producer of uncoated free sheet paper in North America. As a result they are a_x000D_
major producer of lignin, a relatively low value by-product that is used as a solid fuel to generate process steam_x000D_
and power. Lignin, a substance in the cellular walls of plants, is the second most abundant renewable carbon_x000D_
source on our planet. Domtar has recently produced high-grade USDA Certified bio-based lignin, referred to as_x000D_
BioChoice lignin for potential applications in the energy and chemical industries. For the first time, the_x000D_
proposed research intends to explore Domtar's proprietary BioChoice lignin and derivatives, to be synthesized_x000D_
through this research, for applications in drug delivery. It is expected that this research will result in new_x000D_
intellectual property for Domtar and bring its proprietary material BioChoice into the pharmaceutical realm._x000D_
Domtar's proprietary BioChoice Kraft lignin is produced from the black liquor of the Plymouth mill at a rate of_x000D_
about 50-100 tons per day. While the Plymouth mill was the first commercial demonstration plant, Domtar also_x000D_
has 11 other pulp mills, four of which are in Canada. It is Domtar's intention to build out their lignin capacity in_x000D_
many or all of these facilities as demands and markets grow. Given lignin's low cost, sustainability, resistance_x000D_
to oxidation, biocompatibility and biodegradability it is of interest for use in biomedical applications. Yet to_x000D_
date, very few studies have explored lignin and its derivatives for applications in drug delivery. The goal of the_x000D_
current research is to synthesize and fully characterize BioChoice lignin-based microparticles that provide_x000D_
sustained release of drugs for veterinary applications. The global animal healthcare market, was valued at_x000D_
US$27.8 billion in 2013 and is expected to reach US$41.9 billion in 2019. New technologies that provide_x000D_
controlled delivery of drugs for maintenance of good health and treatment of diseases in companion and_x000D_
commercial animals will further advance this fast growing industry. Growth in this industry in Canada will_x000D_
result in new opportunities for scientists trained in chemistry as well as pharmaceutical and veterinary sciences., agreement title english : Engineering BioChoice Lignin-Based Microparticles for Applications in Veterinary Medicine, agreement title french : Engineering BioChoice Lignin-Based Microparticles for Applications in Veterinary Medicine, agreement number : EGP, agreement value : 25000.0, agreement start date : 2017-06-14, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year. (2017-2018 to 2018-2019), additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier. (2017-2018 à 2018-2019), owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada